Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Immunohistochemistry of LAMP-2 and adipophilin for phospholipidosis in liver and kidney in ketoconazole-treated mice.

Asaoka Y, Togashi Y, Imura N, Sai T, Miyoshi T, Miyamoto Y.

Exp Toxicol Pathol. 2013 Sep;65(6):817-23. doi: 10.1016/j.etp.2012.11.008. Epub 2012 Dec 28.

PMID:
23276623
2.

An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats.

Obert LA, Sobocinski GP, Bobrowski WF, Metz AL, Rolsma MD, Altrogge DM, Dunstan RW.

Toxicol Pathol. 2007 Aug;35(5):728-34.

3.

Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole.

Whitehouse LW, Menzies A, Mueller R, Pontefract R.

Toxicology. 1994 Nov-Dec;94(1-3):81-95.

PMID:
7801332
4.

Ketoconazole-induced hepatic lysosomal phospholipidosis: the effect of concurrent barbiturate treatment.

Pakuts AP, Parks RJ, Paul CJ, Bujaki SJ, Mueller RW.

Res Commun Chem Pathol Pharmacol. 1990 Jan;67(1):55-62.

PMID:
2326549
5.

Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation.

Straub BK, Gyoengyoesi B, Koenig M, Hashani M, Pawella LM, Herpel E, Mueller W, Macher-Goeppinger S, Heid H, Schirmacher P.

Histopathology. 2013 Mar;62(4):617-31. doi: 10.1111/his.12038. Epub 2013 Jan 24.

PMID:
23347084
6.

A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.

Sawada H, Takami K, Asahi S.

Toxicol Sci. 2005 Feb;83(2):282-92. Epub 2004 Sep 1. Erratum in: Toxicol Sci. 2006 Feb;89(2):554.

7.

Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid.

Beauchamp D, Laurent G, Maldague P, Abid S, Kishore BK, Tulkens PM.

J Pharmacol Exp Ther. 1990 Nov;255(2):858-66.

PMID:
2243354
8.

Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate.

Cox JW, Ulrich RG, Wynalda MA, McKenna R, Larsen ER, Ginsberg LC, Epps DE.

Biochem Pharmacol. 1989 Oct 15;38(20):3535-41.

PMID:
2530987
9.

Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug.

Robison RL, Visscher GE, Roberts SA, Engstrom RG, Hartman HA, Ballard FH.

Toxicol Pathol. 1985;13(4):335-48.

10.

Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats.

Agoston M, Orsi F, Fehér E, Hagymási K, Orosz Z, Blázovics A, Fehér J, Vereckei A.

Toxicology. 2003 Aug 28;190(3):231-41.

PMID:
12927377
11.

Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug.

Mosedale M, Wu H, Kurtz CL, Schmidt SP, Adkins K, Harrill AH.

Toxicol Appl Pharmacol. 2014 Oct 1;280(1):21-9. doi: 10.1016/j.taap.2014.06.013. Epub 2014 Jun 23.

PMID:
24967691
12.
14.

Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR Mouse.

Mutsuga M, Asaoka Y, Togashi Y, Imura N, Miyoshi T, Miyamoto Y.

J Toxicol Pathol. 2013 Dec;26(4):429-32. doi: 10.1293/tox.2013-0029. Epub 2013 Dec 26.

15.

Drug-induced phospholipidosis: are there functional consequences?

Reasor MJ, Kacew S.

Exp Biol Med (Maywood). 2001 Oct;226(9):825-30. Review.

PMID:
11568304
16.
17.

NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).

National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,.

Natl Toxicol Program Tech Rep Ser. 2004 May;(512):7-289.

18.

Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects.

Cartwright ME, Petruska J, Arezzo J, Frank D, Litwak M, Morrissey RE, MacDonald J, Davis TE.

Toxicol Pathol. 2009 Dec;37(7):902-10. doi: 10.1177/0192623309348521. Epub .

19.

Gene expression profiling in rat liver treated with compounds inducing phospholipidosis.

Hirode M, Ono A, Miyagishima T, Nagao T, Ohno Y, Urushidani T.

Toxicol Appl Pharmacol. 2008 Jun 15;229(3):290-9. doi: 10.1016/j.taap.2008.01.036. Epub 2008 Feb 14.

PMID:
18355885
20.

Species differences in vacuolation of the choroid plexus induced by the piperidine-ring drug disobutamide in the rat, dog, and monkey.

Koizumi H, Watanabe M, Numata H, Sakai T, Morishita H.

Toxicol Appl Pharmacol. 1986 Jun 15;84(1):125-48.

PMID:
3715860
Items per page

Supplemental Content

Write to the Help Desk